Mobile Site ›
Print Page Email Page

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 80919:
Drug Abuse Survey with Confirmation, Evaluation 3, Urine

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This assay was designed to test for and confirm by gas chromatography-mass spectrometry (GC-MS) the most common classes of drugs of abuse.

 

This test uses the screening technique described under IDOAU/8248 Drug Abuse Survey, Urine, which involves immunologic testing for drugs by class. All positive screening results are confirmed by GC-MS, and quantitated, before a positive result is reported.

 

This test represents the coupling of IDOAU/8248 Drug Abuse Survey, Urine with an automatic confirmation of all positive results by the definitive assay available and described elsewhere (eg, AMPHU/8257 Amphetamines, Urine).

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, marijuana metabolite, opiates, and phencyclidine

 

This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.

Interpretation Provides information to assist in interpretation of the test results

A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU/8257 Amphetamines, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/index.html

 

Creatinine and specific gravity are measured as indicators of specimen dilution.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Not intended for use in employment-related testing.

 

The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS/8421 Drug Screen, Prescription/OTC, Serum or PDSU/88760 Drug Screen, Prescription/OTC, Urine).

 

For situations where chain-of-custody is required, a Chain-of-Custody Kit (Supply T282) is available. See COCH/9426 Chain-of-Custody-Processing.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Screening cutoff concentrations

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 20 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Physicians Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006

2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006

3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188